This is in line with a recent publication, in which an overall survival benefit was dominantly observed in the patient cohort below 65 years of age.10 This might be related to the larger pool of naive T cells in younger AML patients, which are required for the induction of novel anti‐leukaemic immune responses.21 Moreover, immune responses against WT1 and PRAME correlated to prolonged OS and RFS (Figure 5e and f). The gene discussed is WT1; the disease is acute myeloid leukemia.